Background: Immunotherapy for food allergies involves progressive increased exposures to food that result in desensitization to food allergens in some subjects but not tolerance to the food. Therefore new approaches to suppress allergic immunity to food are necessary. Previously, we demonstrated that intranasal immunization with a nanoemulsion (NE) adjuvant induces robust mucosal antibody and T H 17-polarized immunity, as well as systemic T H 1-biased cellular immunity with suppression of pre-existing T H 2-biased immunity. Objective: We hypothesized that immunization with food in conjunction with the nanoemulsion adjuvant could lead to modulation of allergic reactions in food allergy by altering preexisting allergic immunity and enhancing mucosal immunity. Methods: Mice were sensitized to peanut with aluminum hydroxide or cholera toxin. The animals were then administered 3 monthly intranasal immunizations with peanut in the nanoemulsion adjuvant or saline. Mice were then challenged with peanut to examine allergen reactivity. Results: The NE intranasal immunizations resulted in marked decreases in T H 2 cytokine, IgG 1 , and IgE levels, whereas T H 1 and mucosal T H 17 immune responses were increased. After allergen challenge, these mice showed significant reductions in allergic hypersensitivity. Additionally, the NE immunizations significantly increased antigen-specific IL-10 production and regulatory T-cell counts, and the protection induced by NE was dependent in part on IL-10. Control animals immunized with intranasal peanut in saline had no modulation of their allergic response.
Food allergy is an emerging health problem with increasing incidence and severity. [1] [2] [3] There are no approved therapeutic approaches to prevent allergic reactions or alter the T H 2-polarized cellular immunity and cytokines that cause allergic inflammation.
1,4-6 Allergen-specific immunotherapy, which involves administration of progressively increasing amounts of allergen, has been the primary approach to attempt to suppress allergic reactions in these patients. Subcutaneous immunotherapy for food showed some promise for protection against IgE-mediated foodinduced allergic responses; however, systemic adverse reactions to this approach are frequent, preventing successful implementation. [7] [8] [9] Sublingual, oral, and epicutaneous immunotherapy have demonstrated some efficacy in animal models and human trials [10] [11] [12] [13] [14] ; however, these approaches only desensitize some patients, and the protection is rapidly lost after cessation of therapy. Furthermore, there have also been significant adverse events, including anaphylaxis and eosinophilic esophagitis, reported with these therapies. 11, 12 Thus there is an urgent need to develop strategies to induce long-term suppression of T H 2-biased immunity to prevent food-induced allergic responses. 15, 16 The phenotype of immune responses results from unique events surrounding antigen presentation that activate different lymphocyte-signaling pathways. Despite current knowledge on induction of T H 2 immune responses, the specific signaling events that lead to development of an allergic disorder associated with T H 2-biased immunity are not clear. More importantly, once formed, the plasticity of these immune responses has not been determined. Most approaches attempting to treat allergic disease use progressive exposure to allergens on the skin or mucosal surfaces; however, these methods have simply reduced reactions to the antigen by causing temporary desensitization to the allergen. In these situations the T H 2 response returns once antigen administration is discontinued. Thus it would be of value to find a way to induce a more permanent redirection of a pre-existing T H 2 immune phenotype toward a protective mucosal IgA-, T H 1-, and/ or T H 17-biased response and evaluate the effect on T H [17] [18] [19] [20] [21] [22] Based on this observation, we sought to induce T H 1 and T H 17 immune responses in allergic animals using a novel nasal immunization system with a nanoscale oil-in-water emulsion (nanoemulsion [NE]) adjuvant. This adjuvant has been shown to consistently produce strong T H 1-and T H 17-protective immune responses to a variety of microbial antigens. [23] [24] [25] [26] As an example, an experimental NE-based respiratory syncytial virus vaccine induced T H 1/T H 17-polarized immunity and protected against viral challenge in mice, preventing virus-induced T H 2-associated pathology, including eosinophil recruitment. 25 In the present study we use this immunization approach in several mouse models of peanut allergy to test whether induction of T H 1/T H 17-polarized immunity can suppress established T H 2 immune responses and characterize the effect of this activity on suppression of allergic reactions.
METHODS

Antigen and adjuvants
Peanut extract (Greer Laboratories, Lenoir, NC) was used for all intraperitoneal and intranasal immunizations. For oral (intragastric) administration, peanut flour (Byrd Mill, 12% fat, light roast) was solubilized in PBS. Nanoscale emulsion (NE) adjuvant was produced by using a high-speed emulsification of ultrapure soybean oil with cetylpyridinium chloride, Tween 80, and ethanol in water, with the resultant NE droplets averaging 350 to 400 nm diameter. 27, 28 Aluminum hydroxide (alum; alhydrogel) was purchased from InvivoGen (San Diego, Calif). Cholera toxin (CTx) from Vibrio cholera was purchased from List Biological Laboratories (Campbell, Calif). The absence of endotoxin in all reagents was confirmed by using a limulus assay.
Mice and immunizations
Pathogen-free C3H/HeJ and BALB/c mice (female mice, 6-8 weeks old) were purchased from Jackson Laboratory (Bar Harbor, Me). Schedules of immunizations are shown in the figures. Allergic sensitization was induced with intraperitoneal immunization of 20 mg of peanut adsorbed on 2 mg alum or intragastric administration of 1 mg of peanut and 10 mg of CTx. Intranasal immunizations were administered as 12 mL (6 mL per naris) of a formulation containing 20 mg of peanut mixed with 20% NE. Peanut mixed with PBS alone served as a control. Mice were challenged intragastrically with 10 mg of peanut on 6 alternating days during the final 2 weeks of the studies. For systemic challenge, mice were injected intraperitoneally with 100 mg of peanut. Mice were killed 1 day after the final challenge. In IL-10 depletion experiments mice were injected intraperitoneally with 0.1 mg of anti-IL-10 (purified from rabbit ascites fluid 29 ) or control rabbit IgG 12 hours before and 1 and 3 days after each intranasal peanut-NE or peanut-PBS immunization. 
Measurement of serum and mucosal antibodies
Sera were obtained by means of saphenous vein bleeding. Bronchoalveolar lavage (BAL) fluid was collected by lavage of lungs with 0.8 mL of PBS with protease inhibitors immediately after death. Peanut-specific IgG, IgA, and IgE antibody levels were determined in serially diluted serum and BAL fluid by using peanut-coated 96-well plates and alkaline phosphatase-conjugated detection antibodies, as described previously. 27 
Analysis of cytokine expression
Spleens and mesenteric lymph nodes (mLNs) were dissected and manually disrupted to generate single-cell suspensions. Red blood cells were depleted from splenocytes with ACK lysing buffer. Lymphocytes were resuspended in culture medium and plated at 8 3 10 5 cells per well in 96-well flat-bottom plates. Cells were cultured ex vivo with or without peanut (5 mg/mL). After 72 hours, cytokine secretion was measured in cell-culture supernatants by using a Luminex Multiplex detection system (Millipore, Billerica, Mass). For each sample, data were determined as follows: ½Peanut stimulated2½Unstimulated 5 Totalðpg=mLÞfor each cytokine ðmean of duplicate determinationsÞ:
Flow cytometry
Lymph node cells were stained by using flow cytometry to quantify regulatory T (Treg) cells. Fc receptors were blocked with purified anti-CD16/ 32 (clone 93; BioLegend, San Diego, Calif), and surface markers were stained with antibodies against CD3 (145-2C11), CD4 (RM4-5), and CD25 (7D4; all from eBioscience, San Diego, Calif, or BD Biosciences, San Jose, Calif); permeabilized, fixed; and labeled for intracellular forkhead box p3 (Foxp3; FJK16s). Data were acquired on an Accuri C6 flow cytometer (BD Biosciences). Data were analyzed with FlowJo software (TreeStar, Ashland, Ore).
Assessment of hypersensitivity reactions
Reactions were evaluated for 1 hour after challenge by using the following scoring system (modified from Li et al 30 and Rodriguez et al 31 ): 0, no symptoms; 0.5, transient rubbing and scratching; 1, prolonged rubbing and scratching around the nose, eyes, or head; 2, puffiness around the eyes or mouth, diarrhea, piloerection, and/or decreased activity with increased respiratory rate; 3, labored respiration, wheezing, stridor, and/or cyanosis around the mouth and tail; 4, tremor, convulsion, no activity after prodding, and/or moribund; and 5, death. Rectal temperature was monitored for 60 minutes after challenge. Mice were bled 30 to 60 minutes after challenge, and serum mouse mast cell protease 1 (MCPT-1) levels were determined by using an ELISA (eBioscience).
Statistics
Results presented here are representative of at least 2 independent reproducible experiments. Statistical comparisons were assessed by using the Mann-Whitney test with GraphPad Prism software (version 6; GraphPad Software, La Jolla, Calif). A P value of less than .05 was considered significant.
RESULTS
Intranasal immunization with NE adjuvant modifies peanut allergy-associated humoral immune responses
C3H/HeJ mice were sensitized with 2 intraperitoneal injections of peanut extract adsorbed on alum, which induces a T H 2-predominant allergic phenotype and allergic reactivity to peanut allergen. [32] [33] [34] Subsequently, these mice received 3 intranasal immunizations with peanut extract formulated in either NE or PBS as a control (Fig 1, A) . Mice were closely monitored after each peanut-NE immunization, and no toxic effects or symptoms of allergic reactions were observed. Peanut-NE-immunized mice had a greater than 10-fold reduction in peanut-specific serum IgE levels (P 5 .0006; Fig 1, B) and significantly greater peanut-specific IgA levels in the BAL fluid (P 5.0361) compared with those in mice not receiving peanut-NE (Fig 1, C) . IgG subclasses in these animals were also quantified as a measure of Tcell polarity. IgG 1 in mice is the result of activation of the T H 2/ IL-4 pathway and has been widely used an indicator of a T H 2 response. 35, 36 Alum sensitization induced predominantly IgG 1 antibodies to the allergen, whereas subsequent NE immunizations significantly increased both IgG 2a and IgG 2b levels (P 5 .0036 and .0008 for IgG 2a and IgG 2b , respectively). There also was a slight but statistically significant (P 5.03) decrease in IgG 1 levels on NE immunization. None of these changes were observed in control mice that received either immunization with peanut in PBS or in animals not subsequently immunized. These findings indicated that mice receiving peanut-NE immunizations had a more balanced allergen-specific antibody response than sensitized mice that did not receive the peanut-NE vaccines.
Intranasal immunization with NE adjuvant suppresses allergy-associated T H 2 cytokine responses mLN cells from these animals were stimulated ex vivo with peanut extract to characterize the recall cellular response both before and after in vivo peanut challenge to confirm that mice receiving peanut-NE immunizations had a shift away from T H 2-biased cellular immunity. On stimulation with peanut extract, cells from peanut-alum-sensitized mice produced predominantly T H 2-type cytokines (IL-4, IL-5, and IL-13) with low levels of T H 1 cytokines (IFN-g and IL-2; Fig 2) . Lymphocytes from mice that received subsequent peanut-NE immunizations produced significantly more T H 1 cytokines and significantly less T H 2 cytokines than sensitized animals that received peanut in saline. Additionally, peanut-NE significantly increased both IL-17 production before challenge and IL-10 production after challenge.
To validate these findings in another food allergy model, we sensitized mice orally using peanut and CTx. 30, 37 As shown in Fig 3, CTx sensitization also induces a T H 2-skewed immunophenotype. Similar to mice sensitized with alum, this CTx-induced immune response could be suppressed and redirected toward T H 1 and T H 17 through NE immunization. Although levels of both IL-17 and IL-10 are increased in peanut-NE-treated mice compared with (Fig 1, B) , as well as BAL fluid peanut-specific IgA titers (Fig 1, C) and serum peanut-specific IgG antibody subclass titers (Fig 1, D) , were determined by means of ELISA. Data are expressed as means 6 SDs (n 5 10). *Statistically significant differences: P < .05.
peanut-PBS-treated mice, this increase is amplified dramatically after challenge, suggesting that the 6 oral challenges over 2 weeks cause an expansion of cells producing those cytokines. Of interest, the T H 2 suppression observed after NE immunization is much greater in mice sensitized with CTx compared with those sensitized with alum. These results demonstrate that the NE adjuvant is able to suppress T H 2 responses induced through different routes of sensitization in mouse models of peanut allergy.
Redirection of allergen-specific T H 2 responses protects against oral peanut challenge
We sought to determine whether NE immunization suppression of T H 2 immune responses translated into protection from allergic reactions after oral challenge with peanut. Mice were sensitized intraperitoneally with peanut-alum or intragastrically with peanut-CTx and immunized intranasally with either peanut-NE or peanut-saline, as described above. Mice sensitized by using either method had a significant reaction to oral peanut challenge, including pruritus, puffiness around the eyes and mouth, and piloerection; labored respiration or wheezing was observed in approximately 20% of the animals (Fig 4) . Mice that received the NE vaccine were significantly protected from these reactions and did not exhibit any symptoms other than rubbing their face and head. Consistent with these observations, CTx-sensitized mice and CTx-sensitized mice immunized intranasally with peanut in saline had significant increases in MCPT-1 levels in their sera (indicating mast cell degranulation). In contrast, mice that received intranasal immunizations of peanut in NE had significantly lower levels of serum MCPT-1. harvested from mice at week 14 either before or after allergen challenge. PBS control mice were not sensitized but were challenged with peanut. Cytokine secretion in culture supernatants was determined by using a Luminex multiplex assay. Cytokine production has been normalized to control unstimulated lymphocyte cultures. Data are expressed as means 6 SDs (n 5 8). *Statistically significant differences: P < .05. A, Schedule of sensitization, immunotherapy, and allergen challenge. i.g., Intragastric; i.n., intranasal. B, Cellular recall immune responses to peanut protein were measured in mLN lymphocytes harvested from mice at week 14 either before or after allergen challenge. PBS control mice were not sensitized but were challenged with peanut. Cytokine secretion in culture supernatants was determined by using a Luminex multiplex assay. Cytokine production has been normalized to control unstimulated lymphocyte cultures. Data are expressed as means 6 SDs (n 5 8). *Statistically significant differences: P < .05.
Suppression of T H 2 immune responses by NE confers protection against systemic peanut challenge
Next, we characterized the ability of the NE allergy vaccine to protect against more severe allergic reactions that occur after systemic peanut challenge administered by means of intraperitoneal injection of peanut extract. This route of challenge is often used in murine models of peanut allergy to elicit very severe reactions and anaphylaxis. [37] [38] [39] Sensitized mice displayed much more pronounced allergic reactions and more frequent and severe anaphylaxis after systemic challenge (Fig 5) , including significant decreases in body temperature, an indicator of shock. C3H/HeJ mice immunized intranasally with peanut in NE adjuvant were significantly protected from these serious allergic reactions (Fig 5, A) . These results were confirmed in BALB/c mice that also were protected significantly, with half of these mice showing no reactivity (Fig 5, B) . These findings indicated that the protection was not strain specific.
NE immunization favorably shifts the gut microenvironment for protection against foodinduced allergic reactions
The marked increase in IL-10 levels after in vivo peanut challenge seen in animals that received intranasal peanut-NE immunization suggested a potential role for Treg cells in NE-mediated suppression of T H 2 immunity. To evaluate this, Treg cell frequency (CD4
1
CD25
1 Foxp3
1
) was measured in mLNs of alum-sensitized animals after oral peanut challenge. Analysis of CD4
CD25
1 Foxp3 1 T cells showed that nasal administration of peanut-NE induced significantly more Treg cells than seen in mice immunized with peanut in saline (P 5 .0095; Fig 6, A) . Levels of allergy-associated cytokines were also measured in lymphocytes from the mLNs after challenge. NE-immunized mice had a significant reduction in IL-33 levels, suggesting that these mice were also protected from epithelial cell damage. NE immunization also suppressed IL-21 and enhanced IL-22, further indicating that NE immunization induces a shift in the immune microenvironment that suppresses allergic reactions.
NE immunization protects against food-induced allergic reactions through IL-10
Mice were sensitized with peanut-alum and IL-10 was depleted at the time of peanut-NE immunization to determine the role of IL-10 in NE-mediated protection against allergic reactions. IL-10 was not depleted during the sensitization or challenge phases. Protection from core body temperature decrease and other clinical symptoms of anaphylaxis was partially lost in IL-10-depleted mice (Fig 6, C and D) . IL-10 depletion completely abolished any protection from mast cell degranulation, as measured based on serum levels of MCPT-1 (Fig 6, E) . IL-10 depletion during the time of NE immunization also resulted in increased peanutspecific IgE levels (Fig 6, F) . These data demonstrate that IL-10 induction is one of the mechanisms by which NE suppresses food allergy.
DISCUSSION
One manner to redirect immune responses is to use adjuvants to cause long-lasting changes in immunity. Adjuvants use different innate immune activators coadministered with antigens to polarize to T H 2-biased (eg, alum) and T H 1-biased (eg, Toll-like receptor 4 ligands) immune responses. [40] [41] [42] We used a unique mucosal NE adjuvant that induces robust T H 1-and T H 17-skewed immune responses in contrast to alum-associated T H 2-biased immunity in identical animal models. [43] [44] [45] In the current studies we demonstrate that just 3 immunizations of intranasal peanut in NE adjuvant can markedly reduce allergic reactions by modulating pre-existing allergen-specific T H 2 immune responses. Intranasal immunization of peanut in NE suppressed established T H 2 responses and IgE production in multiple murine models of peanut allergy, also inducing antigen-specific T H 1 and IL-17 immune responses and increasing mucosal IgA levels. These findings demonstrate uniquely that a mucosal-delivered FIG 4 . NE vaccine protects against oral peanut (PN) challenge. Mice were sensitized with peanut-alum (A) or peanut-CTx (B) and immunized intranasally (i.n.) with 3 administrations of peanut-NE or peanut-PBS. After oral peanut challenge, the clinical anaphylaxis score was characterized, and serum MCPT-1 levels were determined by means of ELISA. *Statistically significant differences: P < .05.
immunization can redirect immune responses toward mucosal and systemic T H 1-and T H 17-polarized immunity while suppressing pre-existing T H 2 immunity.
Animals immunized nasally with peanut in NE had reduced allergic reactions after either oral or systemic peanut challenge compared with animals immunized with peanut in saline. The reduced allergic hypersensitivity is not due to simple desensitization from exposure to the allergen because the adjuvant increased T H 1-associated cytokines, and no protection was observed in mice that received peanut alone administered intranasally. Also, although the NE-immunized animals' peanut-specific IgE levels were somewhat lower than those in saline-immunized animals, their titers of peanut-specific IgE were still increased compared with nonimmunized control values, suggesting the suppressive immune responses were capable of preventing allergic reactions even in the presence of allergen-specific IgE. Finally, the changes in cytokine production observed in the lymph nodes of NE-immunized animals were well beyond what are normally seen with desensitization. 10, 46 This would suggest that induction of T H 1, T H 17, and Treg cells plays a role in reducing allergen reactivity.
Suppression of the symptoms and signs of allergy and anaphylaxis by using this approach potentially has multiple mechanisms. Secreted IgA allows for the clearance of antigen from mucosal surfaces without triggering complement activation, reducing antigen available to bind to IgE. 47 T H 17 can also alter allergic responses in the lungs in several ways. Exogenous IL-17 has been shown to reduce lung eosinophilic inflammation and airway hyperreactivity in T H 2-sensitized mice through the chemokines IL-4 and IL-5 and the inhibition of the capacity of dendritic cells to skew toward T H 2. [48] [49] [50] Previous studies have shown that the IL-17 induced by intranasal NE is limited to mucosal surfaces and that the systemic IL-17 generated is less than required to exacerbate inflammation. 48, 51 In contrast to reports that suggest IL-17 contributes to lung pathology in the context of high amounts of T H 2 cytokines, 51 our data in these studies indicate that the IL-17 induced by NE is not pathogenic and might help suppress allergic disease under these circumstances. This finding is supported by recent data from other groups documenting the suppressive effects of some T H 17 associated immunity. 52, 53 NE also suppresses IL-21, which has been demonstrated to drive T H 2 allergic airway disease, and enhances FIG 5 . NE vaccine protects against systemic peanut (PN) challenge in alum-induced allergy model. C3H/HeJ (A) or BALB/c (B) mice were sensitized with peanut-alum and immunized intranasally with 3 administrations of peanut-NE or peanut-PBS. After intraperitoneal peanut challenge, body temperature was measured, and clinical anaphylaxis scores were characterized. Data are representative of at least 2 independent experiments. *Statistically significant differences: P < .05. Cytokine secretion in culture supernatants was determined by using a Luminex multiplex assay. Cytokine production has been normalized to control unstimulated lymphocyte cultures. C-F, Mice were sensitized with peanut-alum and immunized intranasally with 3 administrations of peanut-NE or peanut-PBS. After intraperitoneal peanut challenge, body temperature, clinical anaphylaxis score, serum MCPT-1 level, and serum peanut-specific IgE level were characterized. Data are representative of at least 2 independent experiments and expressed as means 6 SDs. *Statistically significant differences: P < .05.
IL-22, a cytokine that protects against allergic lung inflammation. 54, 55 Therefore the shift in cellular immune responses induced by NE immunization is likely central to suppressing the allergic phenotype.
Cytokine production from lymphocytes harvested after challenge was often significantly greater than that from lymphocytes harvested at the end of the immunotherapy protocol from mice that had not been challenged. This is likely due to the expansion of peanut-reactive cells, as well as increased homing to the gut, over the 2-week course of oral challenge. It is also interesting that immunizing with NE had a much larger suppression of peanutspecific IL-4 and IL-13 compared with IL-5, especially in cells harvested after allergen challenge (Figs 2 and 3) . These mice were protected from allergic reactions, despite having significant levels of IL-5. Suppression of IL-4 and IL-13 might be central to blocking allergic reactions, as has been recently demonstrated with dupilumab, an anti-IL-4 receptor a subunit antibody that blocks signaling by both IL-4 and IL-13. Clinical trials indicate that it has superior activity in suppressing allergic inflammation in multiple tissues compared with IL-5 blocking antibodies. 14 Overall, peanut-NE more fully suppresses T H 2-associated immune responses in the CTx model compared with the alum model. This might simply be due to the fact that cytokine secretion was much higher in the alum model, and therefore the NE vaccines were able to almost completely suppress the T H 2 response. Additionally, in the alum model the NE-induced increase in IFN-g and IL-10 levels was significantly greater than in the CTx model. It is interesting that although the suppression of T H 2 was different in both models it was sufficient to almost fully protect the mice from oral challenge. This suggests that T H 2 suppression might not be the only factor in suppression of allergic responses and that the overall T H 1/T H 2 balance of the cellular immune environment can influence disease severity.
Antigen-specific Treg cell counts and IL-10 levels were increased in the lymph nodes of these animals after NE immunization. Treg cells have been shown to suppress asthma through IL-10 and TGF-b, 56, 57 and the marked increase in both Treg cell numbers in the lymph nodes and a corresponding increase in IL-10 levels suggest that these factors likely play a role in suppression of the T H 2 immune response by NE. Treg cells also play a critical role in maintenance of immune homeostasis and are an important checkpoint for limiting immune responses. 58, 59 Interestingly, despite either the presence or absence of prior T H 2 immune responses, we clearly show that the NE vaccine induces strong and protective T H 1/T H 17-biased immunity. Thus induction of Treg cells by NE does not appear to inhibit initiation of T H 1-associated immune responses but might be crucial for inhibition of the opposing T H 2 immune responses.
After allergen challenge, mice that received the NE vaccines had reduced IL-33 and IL-21 and enhanced IL-22 levels. Along with suppression of T H 2-associated cytokines, this suggests that NE immunization induces a favorable shift in the immune microenvironment that leads to suppression of allergic reactions. IL-10 was depleted during each intranasal immunization to further elucidate the mechanism of action of the NE allergy vaccine. Depletion of IL-10 significantly increased the severity of allergic reactions in the NE-immunized group, including a complete loss of protection against mast cell degranulation. IL-10 depletion also significantly reversed protection against body temperature loss, as well as anaphylaxis scores. Interestingly, these 2 parameters were still slightly lower than those in mice that did not receive the NE vaccines, suggesting that NE induces protection by multiple mechanisms. IL-10 has been shown to be protective against allergic disease through suppression of T H 2 immune responses, as well as reduction of FcεRI, on mast cells. 57, [60] [61] [62] [63] [64] There are limitations to studies of allergic disease in mice. In addition to differences between mice and human subjects, alum and CTx sensitization do not exactly mimic natural T H 2 food allergy. Thus further studies in the context of more natural allergic disease are necessary to demonstrate the ability of NE nasal immunization to suppress food allergies. However, it is reassuring that our data show the observed effects are not specific to one mouse strain or model of peanut allergy induction. In addition, responses in mice to either anti-IgE or dupilimab 14, 65 led to therapeutic utility in human subjects, demonstrating some value of these models for the development of therapeutics. Furthermore, because significant allergic suppression was observed in multiple models of allergy with either oral or systemic exposure to allergen, it is possible that this approach could be applied to various diseases associated with T H 2-mediated immunity.
Oral allergy immunotherapy can induce serious allergic reactions in allergic subjects. NE mixed with allergen encapsulates antigen in nanoscale oil droplets that sequester the allergen from mucosal IgE antibodies and mast cells and has not caused local release of inflammatory mediators or rhinitis in rodents, dogs, and human subjects. 26, 27, 66, 67 This is supported by a recent study using CpG and peanut-loaded nanoparticles to increase the efficacy and safety of oral immunotherapy for peanut allergy, which demonstrated that by encapsulating the allergen in nanoparticles, anaphylactic reactions to the allergen were prevented. 46 Along with our data, this suggests that sequestering allergen in nanoparticles can increase the safety of immunotherapy.
The study by Srivastava et al 46 demonstrated similar suppression of T H 2-associated immune responses and IgE and induction of IFN-g and IL-10, as well as a corresponding protection from challenge. An increase in Treg cell counts and IL-10 levels has also been reported after epicutaneous immunotherapy in mice. 10, 68 Other groups have demonstrated that allergen immunotherapy in patients with grass pollen allergy not only decreases T H 2 immune responses but also increases numbers of allergenspecific IFN-g-and IL-10-producing cells, as well as Treg cells, and this correlated with improved symptoms. 61, 62 Additionally, proliferating allergen-specific T cells have been found in healthy control subjects lacking grass or peanut allergy, suggesting that nonallergic subjects might be protected because of the presence of T H 1-producing allergen-specific cells. 63, 64 Taken together, these studies suggest that successful immunotherapy occurs not only with the suppression of T H 2 immune responses but that induction of T H 1-polarized immune responses to allergens might be associated with protection from allergic reactions.
Administering allergen with NE appears to induce long-term memory responses, potentially providing benefits even without daily allergen administration. This is supported by the peanut challenge cytokine profiles in sensitized mice after nasal immunization with peanut in NE. Oral challenges began 2 weeks after the last peanut-NE dose and continued for another 2 weeks. Despite being 4 weeks since the last peanut-NE immunization, these animals no longer demonstrated a T H 2 response. In human subjects sustained unresponsiveness has been tested at 2 to 6 weeks after cessation of therapy, with less than half of the patients retaining protection. 
